Your browser doesn't support javascript.
loading
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Delaloge, S; Pérol, D; Courtinard, C; Brain, E; Asselain, B; Bachelot, T; Debled, M; Dieras, V; Campone, M; Levy, C; Jacot, W; Lorgis, V; Veyret, C; Dalenc, F; Ferrero, J M; Uwer, L; Kerbrat, P; Goncalves, A; Mouret-Reynier, M A; Petit, T; Jouannaud, C; Vanlemmens, L; Chenuc, G; Guesmia, T; Robain, M; Cailliot, C.
Affiliation
  • Delaloge S; Department of Cancer Medicine, Institut Gustave Roussy, Villejuif suzette.delaloge@gustaveroussy.fr.
  • Pérol D; Department of Biostatistics, Centre Léon Bérard, Lyon.
  • Courtinard C; Department of Research and Development, R&D Unicancer, Paris.
  • Brain E; Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud.
  • Asselain B; Department of Research and Development, R&D Unicancer, Paris.
  • Bachelot T; Department of Biostatistics, Centre Léon Bérard, Lyon.
  • Debled M; Department of Medical Oncology, Institut Bergonié, Bordeaux.
  • Dieras V; Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud.
  • Campone M; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes and Angers.
  • Levy C; Department of Medical Oncology, Centre François Baclesse, Caen.
  • Jacot W; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier.
  • Lorgis V; Department of Medical Oncology, Centre Georges François Leclerc, Dijon.
  • Veyret C; Department of Medical Oncology, Centre Henri Becquerel, Rouen.
  • Dalenc F; Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse.
  • Ferrero JM; Department of Medical Oncology, Centre Antoine Lacassagne, Nice.
  • Uwer L; Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy.
  • Kerbrat P; Department of Medical Oncology, Centre Eugène Marquis, Rennes.
  • Goncalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille.
  • Mouret-Reynier MA; Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand.
  • Petit T; Department of Medical Oncology, Centre Paul Strauss, Strasbourg.
  • Jouannaud C; Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims.
  • Vanlemmens L; Department of Medical Oncology, Centre Oscar Lambret, Lille.
  • Chenuc G; Capionis, Paris, France.
  • Guesmia T; Department of Research and Development, R&D Unicancer, Paris.
  • Robain M; Department of Research and Development, R&D Unicancer, Paris.
  • Cailliot C; Department of Research and Development, R&D Unicancer, Paris.
Ann Oncol ; 27(9): 1725-32, 2016 09.
Article in En | MEDLINE | ID: mdl-27436849
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Paclitaxel / Bevacizumab Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Middle aged Language: En Year: 2016 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Paclitaxel / Bevacizumab Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Middle aged Language: En Year: 2016 Type: Article